A Study of CRD3874-SI in People With Leukemia
The purpose of this study is to find out whether CRD3874-SI is a safe treatment for participants with acute myeloid leukemia (AML).
Trial Details
- NCT ID
- NCT07661095
- Phase
- PHASE1
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- RECRUITING
- Cancer Type
- Leukemia
- Interventions
- Locations (sample)
- Basking Ridge, New Jersey, United States|40.70621,-74.54932
- Middletown, New Jersey, United States|40.39428,-74.11709
- Montvale, New Jersey, United States|41.04676,-74.02292
- Commack, New York, United States|40.84288,-73.29289
- Harrison, New York, United States|40.96899,-73.71263
Key Eligibility Criteria
- Documentation of Disease
- o Participant has relapsed or refractory acute myeloid leukemia, defined as bone marrow blasts ≥ 5%, and/or reappearance of blasts in the blood in …
- Participant must be ≥ 18 years of age at the time of signing the informed consent form (ICF).
- Participant must weigh at least 40 kg
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Leukemia Trials on Trialify →